Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050918 · ClinicalTrials.gov registry record · NA
Discharge Follow-up Phone Call Program
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 3,054
- Enrollment target
NCT03050918: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT03050918 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 3,054 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (118% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03050918, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,054 participants
- Enrollment target
Study Summary
The goal of this project is to quantify the impact of post-hospital discharge follow-up phone calls on hospital readmission, ED visits, patient satisfaction, and mortality in a general medicine inpatient population. We will obtain exploratory information on patient sub-groups at high risk for hospital readmission and on those experiencing high benefit from the follow-up phone call intervention. In addition, we will obtain data on discharge plan implementation assistance needed to support a successful transition from inpatient to outpatient care among those reached by the intervention phone call.
Primary Outcome
Number of participants with in-patient re-admissions
Interventions
- BEHAVIORAL Follow-up Phone Call
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,054 participants |
| Start Date | 2017-02-20 |
| Est. Completion | 2018-04-15 |
| Phase | NA |
What the finished NCT03050918 record still lists
NCT03050918 is an interventional study that assigns participants to a tested intervention. Its 3,054 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (118% higher).
The record links to 0 conditions, and to 1 intervention - of which Follow-up Phone Call is the first listed.
NCT03050918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03050918 about?
NCT03050918 is a clinical study titled "Discharge Follow-up Phone Call Program". The goal of this project is to quantify the impact of post-hospital discharge follow-up phone calls on hospital readmission, ED visits, patient satisfaction, and mortality in a general medicine inpatient population. We will obtain exploratory information on patient sub-groups at high risk for hospit...
What is the current status of trial NCT03050918?
This trial is currently completed. It is a NA study. The enrollment target is 3,054 participants. The study started on 2017-02-20. Estimated completion is 2018-04-15.
What interventions are being tested in trial NCT03050918?
The interventions under investigation include: Follow-up Phone Call (BEHAVIORAL).
Who is sponsoring clinical trial NCT03050918?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03050918's enrollment target sits among peer trials
3,054 40th of 2000 higher than 1,961 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI